EBOS trims FY26 earnings guidance as fuel costs bite healthcare distribution network

An announcement from EBOS Group Limited ( (AU:EBO) ) is now available.

EBOS Group has warned that sharply higher fuel prices and broader energy cost pressures are lifting transport, consumables and logistics expenses across its operations, particularly within its distribution-heavy businesses. With underlying demand remaining stable, the company says service continuity requirements, government arrangements such as the Community Service Obligation and customer affordability are limiting its ability to fully and immediately pass on these cost increases.

As a result, EBOS has trimmed its FY26 underlying EBITDA outlook to approximately A$610–A$620 million, down from prior guidance of A$615–A$635 million, reflecting an additional A$5–A$10 million in costs absorbed to maintain service levels rather than any deterioration in demand or long-term earnings profile. The Group is pursuing efficiency and mitigation measures, expects these actions to partly offset higher costs in FY27, and is in discussions with stakeholders, including the Australian Government, over fuel cost recovery, though the timing and outcome remain uncertain.

The most recent analyst rating on (AU:EBO) stock is a Buy with a A$29.00 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a major healthcare distributor operating across Australia and New Zealand, supplying medicines, medical products and related consumables through distribution‑intensive businesses such as Symbion. The Group plays an essential role in the regional healthcare supply chain, focusing on uninterrupted and reliable service to pharmacies, hospitals, customers and patients.

Average Trading Volume: 155,480

Technical Sentiment Signal: Sell

Current Market Cap: A$3.89B

See more insights into EBO stock on TipRanks’ Stock Analysis page.